Top Markets
Coin of the day
In Veritas Medical Diagnostics, Inc. In Veritas Medical Diagnostics, Inc.

In Veritas Medical Diagnostics, Inc.

IVME
株式のランク #41113
In Veritas Medical Diagnostics, Inc. (IVME) is a company currently in its... In Veritas Medical Diagnostics, Inc. (IVME) is a company currently in its development phase, dedicated to researching and creating advanced medical devices for point-of-care diagnostics. Their leading product is a prothrombin monitor, which assesses blood coagulation in patients at risk of cardiovascular diseases and strokes. The company is also actively developing an array of other diagnostic tools. These include a consumer-oriented device to predict the onset of labor for maternity planning, a comprehensive biomarker monitor capable of identifying indicators for conditions such as heart attacks, HIV, cholesterol levels, and cancer. Further innovations under development feature a non-invasive device for continuous blood glucose concentration measurement, a digital scanning machine designed as a non-invasive alternative to traditional 2D X-rays, and an osteoporosis device providing instant bone mineral density readings for patients. Additionally, they are working on a portable digital strip reader for immunoassay applications. Formerly known as In Vivo Medical Diagnostics, Inc., the company officially adopted its current name in 2005. Its operations are headquartered in Inverness, United Kingdom.
株価
$0.0007
最終同期: 2025-09-02
時価総額
$42.26K
変化(1日)
0.00%
変化(1年)
0.00%
GB
取引 In Veritas Medical Diagnostics, Inc. (IVME)

カテゴリー

In Veritas Medical Diagnostics, Inc.(IVME)のP/E比率
2026 時点のP/E比率 TTM 0
In Veritas Medical Diagnostics, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は 0 です。2026 年末時点での P/E は 0 でした。
In Veritas Medical Diagnostics, Inc. の P/E 比率の履歴(2026 〜 2026)
各年末のP/E比率
P/E比率 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社のP/E比率
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。